Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.33 |
| ▸ | UTS2R | Q9UKP6 | 6/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2868669 | 1.00 | CNR2 (0.34) | CNR2PTGDR2UTS2RTRPV1TRPM8 | |
| SCHEMBL2837496 | 0.93 | CNR2 (0.34) | CNR2PTGDR2TRPV1TRPM8CNR1 | |
| SCHEMBL2837497 | 0.93 | CNR2 (0.34) | CNR2PTGDR2TRPV1TRPM8CNR1 | |
| SCHEMBL2872819 | 0.92 | TRPM8 (0.35) | CNR2PTGDR2TRPV1TRPM8CNR1 | |
| SCHEMBL2872822 | 0.92 | TRPM8 (0.35) | CNR2PTGDR2TRPV1TRPM8CNR1 | |
| SCHEMBL2873987 | 0.91 | UTS2R (0.33) | CNR2UTS2RCNR1HSP90AA1HSP90AB1 | |
| SCHEMBL2873991 | 0.91 | UTS2R (0.33) | CNR2UTS2RCNR1HSP90AA1HSP90AB1 | |
| SCHEMBL4231666 | 0.91 | CNR2 (0.37) | CNR2TRPV1TRPM8CNR1 | |
| SCHEMBL4231664 | 0.91 | CNR2 (0.37) | CNR2TRPV1TRPM8CNR1 | |
| SCHEMBL2837583 | 0.89 | CNR2 (0.40) | CNR2PTGDR2TRPV1TRPM8CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245020-B1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-01-15 | — | — | EP | claimed |
| EP-2245020-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2010-11-03 | — | — | EP | claimed |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-09-03 | — | — | US | claimed |
| WO-2009086163-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | WO | claimed |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | claimed |
| EP-2245020-B1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8383657-B2 | Thiazolylidine urea and amide derivatives and methods of use thereof | ABBOTT LABORATORIES (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2245020-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2009086163-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | NMUR1, NMUR2, PAM | CNR2 156/4885PTGDR2 615/4885UTS2R 5/4885 |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | CHRNA4, CHRNA5, CHRNA3 | CNR2 91/4885PTGDR2 570/4885UTS2R 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.